3,053 results match your criteria hyperthermic intraperitoneal


Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy with and without Diaphragmatic Resection in Patients with Peritoneal Metastases.

Ann Surg Oncol 2021 Sep 21. Epub 2021 Sep 21.

Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 Saint Paul Place, Baltimore, MD, 21202, USA.

Background: Diaphragmatic resection (DR) is often required during cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) to achieve complete cytoreduction (CC). While CC provides the best survival, requiring a DR may indicate unfavorable tumor biology. We assessed how DR during CRS/HIPEC affects outcomes. Read More

View Article and Full-Text PDF
September 2021

Quick diagnosis of pleural effusion secondary to chemotherapy infusion during cytorreductive surgery and hyperthermic intraperitoneal chemotherapy.

Rev Esp Anestesiol Reanim 2021 Sep 17. Epub 2021 Sep 17.

Departamento de Anestesiología, Hospital Universitario Son Espases, Palma, Islas Baleares, España.

View Article and Full-Text PDF
September 2021

Survival and complications of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients: a systematic review and meta-analysis.

Eur Rev Med Pharmacol Sci 2021 Sep;25(17):5330-5348

Department of Interventional Radiotherapy, Huzhou Cent Hospital, Affiliated Cent Hospital HuZhou University, Zhejiang Province, P.R. China.

Objective: Peritoneal cancer is an uncommon form of terminal malignancy with substantial morbidity and mortality. While both young and elderly population groups with peritoneal cancer are treated by joint cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, studies suggest that they might have a differential prognostic outcome in terms of postoperative morbidity and mortality. To date, only one review has attempted to evaluate the comparative impact of postoperative complications and overall mortality in these age groups. Read More

View Article and Full-Text PDF
September 2021

ASO Visual Abstract: Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy With and Without Diaphragmatic Resection in Patients with Peritoneal Metastases.

Ann Surg Oncol 2021 Sep 16. Epub 2021 Sep 16.

Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, MD, 21202-2001, USA.

View Article and Full-Text PDF
September 2021

The Impact of Sarcopenia in Patients with Peritoneal Surface Disease.

Pathol Oncol Res 2021 30;27:638857. Epub 2021 Aug 30.

Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA, United States.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Read More

View Article and Full-Text PDF

Contribution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Videos on YouTube to the Learning Curve in COVID-19 Pandemic Process.

Cureus 2021 Aug 2;13(8):e16820. Epub 2021 Aug 2.

General Surgery, Ankara City Hospital, Ankara, TUR.

Introduction: YouTube is a free video-sharing platform, which is watched by residents or specialists in order to catch up on their skills, see new techniques, and have information. In this study, our purpose is to evaluate whether or not these videos are an appropriate educational source for surgeons by analyzing their quality and content, in an environment of reduced elective operations due to the COVID-19 pandemic.

Methods: YouTube video search was performed by entering keywords such as CRS and HIPEC, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, cytoreductive surgery, and HIPEC. Read More

View Article and Full-Text PDF

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin: A Single Center Experience.

Front Surg 2021 26;8:715119. Epub 2021 Aug 26.

Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Pseudomyxoma peritonei (PMP) originating from appendiceal mucinous neoplasm is a rare peritoneal malignancy characterized by the progressive intraperitoneal accumulation of mucus leading to death if left untreated. In recent years, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offered increased survival rates. This study aims to identify the clinical, pathological, and surgical features influencing safety and survival outcomes of patients undergoing CRS and HIPEC for PMP of appendiceal origin. Read More

View Article and Full-Text PDF

Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.

J Gastrointest Surg 2021 Sep 10. Epub 2021 Sep 10.

Department of Surgery, Johns Hopkins University, 600 N. Wolfe Street/Blalock 609, Baltimore, MD, 21287, USA.

Background: Tumor markers are commonly utilized in the diagnostic evaluation, treatment decision making, and surveillance of appendiceal tumors. In this study, we aimed to determine the prognostic significance of elevated preoperative tumor markers in patients with pseudomyxoma peritonei secondary to low-grade appendiceal mucinous neoplasm who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Methods: Using a multi-institutional database, eligible patients with measured preoperative tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), or cancer antigen 125 (CA-125)] were identified. Read More

View Article and Full-Text PDF
September 2021

Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study).

Br J Surg 2021 Sep 9. Epub 2021 Sep 9.

Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon, Lyon, France.

Background: The incidence of gastric poorly cohesive carcinoma (PCC) is increasing. The prognosis for patients with peritoneal metastases remains poor and the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is controversial. The aim was to clarify the impact of gastric PCC with peritoneal metastases treated by CRS with or without HIPEC. Read More

View Article and Full-Text PDF
September 2021

Corrigendum to "Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients".

Biomed Res Int 2021 23;2021:9789613. Epub 2021 Aug 23.

Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, China.

[This corrects the article DOI: 10.1155/2021/5533134.]. Read More

View Article and Full-Text PDF

Pelvic exenteration, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: experience and outcomes from an exenterative and peritonectomy unit.

Langenbecks Arch Surg 2021 Sep 8. Epub 2021 Sep 8.

Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Purpose: Pelvic exenteration (PE) for locally advanced pelvic malignancy is well established, though high rates of morbidity and mortality exist. Such a complication profile has often deterred the surgical community from offering exenteration in combination with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). We aimed to evaluate the perioperative outcomes following pelvic exenteration when combined with CRS and HIPEC for peritoneal surface malignancy (PSM) in a tertiary referral centre. Read More

View Article and Full-Text PDF
September 2021

ASO Visual Abstract: Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin-A Single Center Observational Study.

Ann Surg Oncol 2021 Sep 7. Epub 2021 Sep 7.

Department of Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

View Article and Full-Text PDF
September 2021

Laparoscopic total pelvic peritonectomy for colorectal cancer pelvic carcinomatosis: a retrospective case series and photographic/videographic step-by-step guide.

Surg Endosc 2021 Sep 7. Epub 2021 Sep 7.

Division of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan.

Background: Cytoreductive surgery (CRS) for colorectal cancer peritoneal carcinomatosis has been shown to prolong survival with acceptable morbidity rates. Total pelvic peritonectomy (TPP), or complete removal of all pelvic peritoneum, constitutes an important and technically challenging component of CRS. Here we report our experience and describe our technique of laparoscopic total pelvic peritonectomy (LTPP), using a photographic/videographic step-by-step guide. Read More

View Article and Full-Text PDF
September 2021

Oncologic Emergencies.

AACN Adv Crit Care 2021 Sep;32(3):306-314

Garry J. Brydges is Director, Anesthesia Safety and Quality, Department of Anesthesiology, Division of Anesthesia, Critical Care and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

A new cancer diagnosis is expected to affect approximately 1.9 million people in the United States in 2021. A small percentage of these patients will experience an emergent cancer-related complication. Read More

View Article and Full-Text PDF
September 2021

Immunomodulating Therapy by Picibanil-based Imiquimod and Virotherapy for Advanced Uterine Cancer after Laparoscopic Surgery.

Gynecol Minim Invasive Ther 2021 Jul-Sep;10(3):191-194. Epub 2021 Aug 3.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Linkou Medical Center, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.

This is a case report of a uterine cancer with the International Federation of Gynecology and Obstetrics staging 3c2 with the initial clinical presentation of postmenopausal vaginal bleeding in August 2015. Endometrium biopsy showed invasive nests of poorly differentiated grade 3 endometrioid adenocarcinoma. The patient received robotic surgery including total hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, para-aortic lymph node dissection, and washing cytology. Read More

View Article and Full-Text PDF

Nomogram to Predict Incomplete Cytoreduction for Pseudomyxoma Peritonei.

Ann Surg Oncol 2021 Sep 3. Epub 2021 Sep 3.

Clinical Laboratory Medicine, Peking University Ninth School of Clinical Medicine, Beijing, China.

Backgrounds: The completeness of cytoreduction is one of the most important prognostic factors for patients with pseudomyxoma peritonei (PMP). To date, no nomograms have been established to predict incomplete cytoreduction (IC) for patients with PMP. The current study therefore proposed a nomogram to predict individual IC risk for PMP patients. Read More

View Article and Full-Text PDF
September 2021

ASO Visual Abstract: Impact of Insurance Status on Oncologic and Perioperative Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Ann Surg Oncol 2021 Sep 3. Epub 2021 Sep 3.

Section of Surgical Sciences, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article and Full-Text PDF
September 2021

The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy.

Eur J Surg Oncol 2021 Aug 28. Epub 2021 Aug 28.

Department of Surgery, Aarhus University Hospital, Denmark.

Introduction: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) has become the mainstream treatment for peritoneal metastases of colorectal origin. This extensive treatment is known for its increased morbidity rate. In this study, the impact of postoperative complications on survival was evaluated in a high-volume centre. Read More

View Article and Full-Text PDF

Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS+HIPEC for Peritoneal Surface Malignancy.

Ann Surg Oncol 2021 Aug 30. Epub 2021 Aug 30.

Manipal Comprehensive Cancer Centre, Manipal Hospital, Bangalore, India.

Background: Anastomotic leak after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) remains a dreaded complication. There is no consensus statement regarding the optimal timing for bowel anastomoses to perform after or before HIPEC.

Methods: Patients who underwent CRS+HIPEC and had at least one bowel anastomosis were retrospectively analyzed to evaluate if timing of anastomosis done after or before HIPEC had an impact on bowel complication rates (anastomotic leak and perforation). Read More

View Article and Full-Text PDF

ASO Author Reflections: Disparate Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Based on Insurance Status.

Ann Surg Oncol 2021 Aug 28. Epub 2021 Aug 28.

Section of Surgical Sciences, Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article and Full-Text PDF

Incidence, Risk Factors, and Outcomes from Conversion of Low-Grade to High-Grade Appendiceal Neoplasms for Patients Undergoing Multiple Cytoreductive Surgeries with Hyperthermic Intraperitoneal Chemotherapy.

Ann Surg Oncol 2021 Aug 28. Epub 2021 Aug 28.

Division of Surgical Oncology, Wake Forest Baptist Health Medical Center, Winston-Salem, NC, USA.

Introduction: Conversion from low-grade to high-grade disease is known to occur following repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC); however, the incidence rate, risk factors, and outcomes have not been studied.

Methods: We conducted a retrospective review of multiple CRS/HIPEC cases for patients originally diagnosed with low-grade appendiceal neoplasms, and compared converted cases with non-converters. Primary outcomes were the incidence rate and risk factors for conversion, while secondary outcomes were effect on cytoreduction, overall survival (OS), and disease-free survival (DFS). Read More

View Article and Full-Text PDF

Misdiagnosis of appendiceal neoplasms as ovarian tumors: Impact of prior gynecologic surgery on definitive cytoreduction and HIPEC.

Eur J Surg Oncol 2021 Aug 24. Epub 2021 Aug 24.

Colon and Rectal Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, NY, 10021, USA. Electronic address:

Background: Female patients with pelvic/adnexal masses often undergo gynecologic operations due to presumed ovarian origin. The diagnosis of an appendiceal tumor is often only made postoperatively after suboptimal cytoreduction has been performed. We hypothesized that an index gynecological procedure increases the morbidity of definitive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with appendiceal mucinous tumors. Read More

View Article and Full-Text PDF

Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

World J Surg Oncol 2021 Aug 26;19(1):253. Epub 2021 Aug 26.

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Background: The impact of primary tumour location on the prognosis of patients with peritoneal metastasis (PM) arising from colorectal cancer (CRC) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is rarely discussed, and the evidence is still limited.

Methods: Patients with PM arising from CRC treated with CRS and HIPEC at the China National Cancer Center and Huanxing Cancer Hospital between June 2017 and June 2019 were systematically reviewed. Clinical characteristics, pathological features, perioperative parameters, and prognostic data were collected and analysed. Read More

View Article and Full-Text PDF

Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Ann Surg Oncol 2021 Aug 25. Epub 2021 Aug 25.

Hospital Clínico Universitario, Department of Surgery, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.

Background: The standardization of surgical outcomes throughout surgical procedures is mandatory. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) should provide proficient oncological and surgical outcomes.

Study Design: The aim of this study was to identify clinically relevant quality indicators and their quality standard, and to determine their acceptable quality limit. Read More

View Article and Full-Text PDF

ASO Visual Abstract: Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Ann Surg Oncol 2021 Aug 25. Epub 2021 Aug 25.

Department of Surgery, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario, University of Valencia, Valencia, Spain.

View Article and Full-Text PDF

Impact of Insurance Status on Oncologic and Perioperative Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Ann Surg Oncol 2021 Aug 25. Epub 2021 Aug 25.

Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: A growing body of research has shown that underinsured patients are at increased risk of worse health outcomes compared with insured patients. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is largely performed at highly specialized cancer centers and may pose challenges for the underinsured. This study investigates surgical outcomes following CRS-HIPEC for insured and underinsured patients with peritoneal carcinomatosis. Read More

View Article and Full-Text PDF

Safety and Effectiveness of High-Precision Hyperthermic Intraperitoneal Perfusion Chemotherapy in Peritoneal Carcinomatosis: A Real-World Study.

Front Oncol 2021 6;11:674915. Epub 2021 Aug 6.

Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported to effectively control peritoneal carcinomatosis (PC) in various patient populations, but there is a lack of real-world data. This study aimed to examine the safety and effectiveness of HIPEC in patients with PC in a real-world setting.

Methods: This was a retrospective study of patients with PC treated with the high-precision BR-TRG-I type HIPEC device between December 2006 and December 2016. Read More

View Article and Full-Text PDF